Takuya Yoshimoto

Statistics

Publications

Citations

117

H-Index

Active since

2021

Affiliations

National Cancer Center Hospital East(Current)

Shikoku Cancer Center

Kansai Medical University

The Cancer Institute Hospital

St. Luke's International Hospital

Takuya Yoshimoto is an author at National Cancer Center Hospital East specializing in oncology, pharmacology, and anaplastic lymphoma kinase inhibition.

ORCID

Publications per year

2021–2023

Publications

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

Katsuyuki Hotta, Toyoaki Hida, Hiroshi Nokihara et al. · ESMO Open · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacology +16

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Koh Furugaki, Takaaki Fujimura, Hayato Mizuta et al. · npj Precision Oncology · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).

Hiroshige Yoshioka, Toyoaki Hida, Hiroshi Nokihara et al. · Journal of Clinical Oncology · 2021 · 12 citations

Medicine, Oncology, Pharmacology +16

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm

Yusuke Narita, Takuya Yoshimoto, Tomoyuki Namai et al. · JCO Clinical Cancer Informatics · 2022 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

1–4 of 4